Company Overview and News

 
An evening walk down Dalal Street | Bulls rule D-Street as Sensex soars 461 points; Nifty above 10,450

2018-10-10 moneycontrol
Banking big on lenders, bulls went all guns blazing on D-Street on Tuesday as benchmark indices saw a good surge. Benchmarks ended over a percent higher; the Nifty soared past 10,450-mark.
INDIGO BHRYY GRAPHITE AXB 532617 JETAIRWAYS 532978 532215 539448 AXBKY AXBA BAJAJFINSV BAJFINANCE 534816 AXISBANK BJJQY INFRATEL 509488 500034 SBAZ

 
Indian makers of graphite electrodes offer purest play and most upside; BoAML sees 104% rally in Graphite India

2018-10-10 moneycontrol
Global brokerage house Bank of America Merrill Lynch expanded its coverage of graphite electrodes (GE) with four new Buy ratings globally, including HEG and Graphite India as it believes graphite electrode upcycle becomes a structural story now.
GRAPHITE 509488

 
Graphite India Limited - Updates

2018-10-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GRAPHITE 509488

20
Graphite Miners News For The Month Of September 2018

2018-09-26 seekingalpha - 2
Graphite company news - Several large successful capital raises for graphite companies. Triton Minerals lands Shandong Tianye as a cornerstone investor.
GRXXF URA SRHYY BKR BSSMF LMRMF URLNF URRE EAF ZEYYF GPHEF RNU GPHOF GRAPHITE BSM LLG APMFD NSRC KBBRF CYLYF AMVMF WKT IMYSY FMS GRPH TON ZENYF DNI BKT MUS IMYSF DMNKF SYR 509488 LMR NGPHF TLG LEMIF WWR ZEN FSRCY SYAAF KNL ECORF SVM NSRCF MGPHF URI FCSMF CZSVF

 
Graphite India Limited - News Clarification

2018-09-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GRAPHITE 509488

 
Graphite India Limited - News Clarification

2018-09-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GRAPHITE 509488

 
Graphite India Limited - Updates

2018-09-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GRAPHITE 509488

 
Graphite India slips 5% on Bengaluru plant shutdown report; Jefferies maintains buy

2018-09-21 moneycontrol
Shares of Graphite India slipped 5 percent intraday Friday as there is a media report stating about shutdown of its Bengaluru plant on pollution concerns.
GRAPHITE 509488

 
Graphite India Limited - Updates

2018-09-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GRAPHITE 509488

 
Graphite India Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GRAPHITE 509488

1
Deals Buzz: Vodafone-Idea raises $15 billion via debt

2018-09-04 livemint
India’s largest telecom company after the merger—Vodafone Idea Ltd. Raise $15 billion through non-convertible debentures (NCD) in private placement, the first debt after its incorporation, Press Trust of India reported. The NCDs have maturity period of 5 years and have been offered at interest rate of 10.9% per annum. Idea Cellular Ltd and Vodafone Plc on last Friday announced completion of the ₹23.
GRAPHITE 532480 IDEA ALBK ICLQY CG 532822 509488

 
Graphite India Limited - Acquisition

2018-09-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GRAPHITE 509488

 
Graphite India buys 16% stake in US-based General Graphene for ₹132 crores

2018-09-03 livemint
New Delhi: Graphite India Ltd., the largest Indian maker of graphite electrodes used to melt scrap iron and steel, bought a 16% stake in US-based General Graphene Corporation for ₹132 crores, ($18.6 million) in an all-cash deal, the company said in a stock exchange announcement.
GRAPHITE 509488

 
Graphite India Limited - Press Release

2018-09-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GRAPHITE 509488

 
Graphite India Limited - Acquisition

2018-09-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GRAPHITE 509488

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...